HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination-Reference-Cited by-同舟云学术

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Published:2007-02-26 Issue:1 Volume:7 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Tiezzi Daniel G,Andrade Jurandyr M,Ribeiro-Silva Alfredo,Zola Fábio E,Marana Heitor RC,Tiezzi Marcelo G

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/1471-2407-7-36/fulltext.html

Reference31 articles.

1. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA: Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J. 2006, 12 (2): 159-164. 10.1111/j.1075-122X.2006.00225.x.

2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997, 15 (7): 2483-2493.

3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998, 16 (8): 2672-2685.

4. Amat S, Abrial C, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Cure H, Chollet P: High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005, 94 (3): 255-263. 10.1007/s10549-005-9008-8.

5. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990, 82 (19): 1539-1545. 10.1093/jnci/82.19.1539.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients;European Journal of Breast Health;2022-04-01

2. Prognostic Significance of HER2 Expression Changes Following Neoadjuvant Chemotherapy in Saudi Patients With Locally Advanced Breast Cancer;Clinical Breast Cancer;2021-08

3. Expression of Therapy-Induced Senescence Markers in Breast Cancer Samples Upon Incomplete Response to Neoadjuvant Chemotherapy;Bioscience Reports;2021-05-05

4. Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer;Journal of Oncology;2021-02-12

5. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer;Clinical and Translational Oncology;2021-02-07